CORPORATE MEDIA RELEASE
NHS ENGLAND TO FUND ENDOCUFF VISION® FOR BOWEL CANCER SCREENING COLONOSCOPIES
AMSTERDAM. The Netherlands, 9 April 2018. Norgine B.V. today announced that its UK affiliate has received funding for ENDOCUFF VISION® through the NHS Innovation Technology Payment 2018/19 (ITP) scheme. The NHS ITP Programme aims to support the NHS in adopting innovation by removing financial or procurement barriers to uptake of innovative products or technologies and is a competitive process.
ENDOCUFF VISION® is a single use device attached at the end of the colonoscope that gives an optimal view of the entire colon by retracting folds during withdrawal. ENDOCUFF VISION® will be funded in colonoscopies conducted as part of the bowel cancer screening programme.
ENDOCUFF VISION® significantly improved adenoma detection rate and colorectal cancer detection during colonoscopy in bowel cancer screening patients.[i]
Colorectal cancer is the 4th most common cancer in the UK, accounting for 12% of all new cancer cases. 1 in 14 men and 1 in 19 women will be diagnosed with bowel cancer during their lifetime.[ii]
In the UK and Europe, ENDOCUFF VISION® is available through Norgine and in other parts of the world the product is available through business partners. Norgine owns a majority stake of Arc Medical Design Ltd, the originator of ENDOCUFF VISION®.
Isabelle Jouin, T: +44 (0)1895 826237
Follow us @norgine
[i] Ngu WS, et al. Gut 2018;66:1–9. doi:10.1136/gutjnl-2017-314889
[ii] Cancer Research UK. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer. Accessed 5 April 2018.